RobertDobbinsMD

Endocrinology • Research Triangle Park, NC

Diabetes, Lipid Metabolism

Physician

Join to view full profile

Are you Dr. Dobbins?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 12 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
5 Moore Dr

Research Triangle Park, NC 27709
Phone+1 919-483-7922
Is this information wrong?

Summary

Dr. Robert Dobbins, MD is an endocrinologist in Research Triangle Park, North Carolina. He is currently licensed to practice medicine in Texas and Tennessee.

Education & Training

University of Texas Southwestern Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1996 - 1999
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1993 - 1996
Vanderbilt University School of MedicineClass of 1991

Certifications & Licensure

TX State Medical License 1999 - 2025
TN State Medical License 1996 - 2024

Publications & Presentations

PubMed

133 citations
Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase...
Vinod S. Hegade, Stuart Kendrick, Robert L. Dobbins, Sam R. Miller, Douglas Thompson, Duncan Richards, James Storey, George E. Dukes, Margaret Corrigan, Ronald P.J. Ou...> ;Lancet. 2017 Mar 18
25 citations
BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial
Vinod S. Hegade, Stuart Kendrick, Robert L. Dobbins, Sam R. Miller, Duncan Richards, James Storey, George E. Dukes, Kim Gilchrist, Susan Vallow, Graeme J.M. Alexander,...> ;BMC Gastroenterology. 2016 Jul 19
12 citations
Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment
Robin L. O'Connor-Semmes, Susan Walker, Anita Kapur, Elizabeth K. Hussey, June Ye, Laurene Wang-Smith, Wenli Tao, Robert L. Dobbins, Bentley Cheatham, William O. Wilkison> ;Drug Metabolism and Disposition. 2015 Jul 1
75 citations
Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release
Robert L. Dobbins, Frank L. Greenway, Lihong Chen, Yaping Liu, Sharon L Breed, Susan Andrews, Jeffrey A. Wald, Ann C. Walker, Chari D. Smith> ;American Journal of Physiology. Gastrointestinal and Liver Physiology. 2015 Jun 1
14 citations
GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes. A randomised trial.
Robert L. Dobbins, Robert Byerly, Riley Gaddy, Feng Gao, Kelly M. Mahar, Antonella Napolitano, Philip Ambery, Anne-Charlotte de Gouville> ;European Journal of Pharmacology. 2015 May 15
23 citations
Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes
A. P. Sykes, Robin L. O'Connor-Semmes, Robert L. Dobbins, D. J. Dorey, J. D. Lorimer, S. Walker, W. O. Wilkison, L. Kler> ;Diabetes, Obesity & Metabolism. 2015 Jan 1
22 citations
Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes.
A. P. Sykes, G. L. Kemp, Robert L. Dobbins, Robin L. O'Connor-Semmes, S. R. Almond, W. O. Wilkison, S. Walker, L. Kler> ;Diabetes, Obesity & Metabolism. 2015 Jan 1
26 citations
Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects
Antonella Napolitano, Sam R. Miller, Peter R. Murgatroyd, Elizabeth K. Hussey, Robert L. Dobbins, Edward T. Bullmore, Derek J. Nunez> ;Journal of Clinical & Translational Endocrinology. 2014 Mar 1
25 citations
GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus
Robert L. Dobbins, S. P. Shearn, R. L. Byerly, Feng Gao, Kelly M. Mahar, Antonella Napolitano, G. J. Nachbaur, A. C. Le Monnier de Gouville> ;Diabetes, Obesity & Metabolism. 2013 Nov 1
57 citations
Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes.
Wu Yulin, Christopher Joseph Aquino, David J. Cowan, Don L. Anderson, Jeff L. Ambroso, Michael J. Bishop, Eric E. Boros, Lihong Chen, Alan Cunningham, Robert L. Dobbin...> ;Journal of Medicinal Chemistry. 2013 Jun 6
33 citations
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects ...
Anita Kapur, Robin L. O'Connor-Semmes, Elizabeth K. Hussey, Robert L. Dobbins, Wenli Tao, Marcus Hompesch, Glenn Smith, Joseph W. Polli, Charles D James, Imao Mikoshib...> ;BMC Pharmacology & Toxicology. 2013 May 13
24 citations
Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes ...
Elizabeth K. Hussey, Anita Kapur, Robin L. O'Connor-Semmes, Wenli Tao, Bryan Rafferty, Joseph W. Polli, Charles D James, Robert L. Dobbins> ;BMC Pharmacology & Toxicology. 2013 Apr 30
6 citations
Regional gastrointestinal delivery of remogliflozin etabonate in humans
Robin L. O'Connor-Semmes, Erik P. Sandefer, Elizabeth K. Hussey, Wenli Tao, Walter J. Doll, Richard C. Page, Robert L. Dobbins> ;Biopharmaceutics & Drug Disposition. 2013 Mar 1
8 citations
Reduced T2* Values in Soleus Muscle of Patients with Type 2 Diabetes Mellitus
Chun S. Zuo, Young Hoon Sung, Donald C. Simonson, Erin L. Habecker, Jian Wang, Charlotte A. Haws, Rosemond A. Villafuerte, Michael E. Henry, Robert L. Dobbins, Rebecca...> ;Plos One. 2012 Nov 26
22 citations
Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance, ...
J. Sigafoos, Gary D Bowers, Stephen Castellino, Amanda G. Culp, David S. Wagner, Melinda J. Reese, Joan E. Humphreys, Elizabeth K. Hussey, Robin L. O'Connor Semmes, An...> ;Drug Metabolism and Disposition. 2012 Nov 1
42 citations
Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes
Sunder Mudaliar, Debra Armstrong, Annie A. Mavian, Robin L. O'Connor-Semmes, Patricia K. Mydlow, June Ye, Elizabeth K. Hussey, Derek J. Nunez, Robert R. Henry, Robert ...> ;Diabetes Care. 2012 Nov 1
50 citations
Remogliflozin etabonate, a selective inhibitor of the sodium‐dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients
Robert L. Dobbins, Robin L. O'Connor-Semmes, Anita Kapur, C. Kapitza, G. Golor, I. Mikoshiba, Wenli Tao, Elizabeth K. Hussey> ;Diabetes, Obesity & Metabolism. 2012 Jan 1
3 citations
Assessment of Acute and Chronic Pharmacological Effects on Energy Expenditure and Macronutrient Oxidation in Humans: Responses to Ephedrine
Antonella Napolitano, Peter R. Murgatroyd, Nick Finer, Elizabeth K. Hussey, Robert L. Dobbins, Steve O'Rahilly, Derek J. Nunez> ;Journal of Obesity. 2011 Jan 1
33 citations
Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a r...
Elizabeth K. Hussey, Robert L. Dobbins, Randall Stoltz, Nancy L. Stockman, Robin L. O'Connor-Semmes, Anita Kapur, Sharon C. Murray, Debbi Layko, Derek J. Nunez> ;Journal of Clinical Pharmacology. 2010 Jun 1
40 citations
Single-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 ...
Elizabeth K. Hussey, Richard V. Clark, Dipti M. Amin, Mark Kipnes, Robin L. O'Connor-Semmes, Eilis C. O'Driscoll, Jenny Leong, Sharon C. Murray, Robert L. Dobbins, Deb...> ;Journal of Clinical Pharmacology. 2010 Jun 1
125 citations
Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects.
Mark A. Bush, Jessica E. Matthews, E. H. De Boever, Robert L. Dobbins, Rebecca J. Hodge, Susan E. Walker, M. C. Holland, M. Gutierrez, Murray Stewart> ;Diabetes, Obesity & Metabolism. 2009 May 1
150 citations
Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes
Jessica E. Matthews, Murray Stewart, Erika H. De Boever, Robert L. Dobbins, Rebecca J. Hodge, Susan E. Walker, M. Claire Holland, Mark A. Bush> ;The Journal of Clinical Endocrinology and Metabolism. 2008 Dec 1
5 citations
MRI assessment of drug-induced fluid accumulation in humans: validation of the technology.
Chun S. Zuo, Rosemond A. Villafuerte, Michael E. Henry, Robert L. Dobbins, Chunnin Lee, Young Hoon Sung, Charlotte A. Haws, Michelle L. Butman, Sam R. Miller, Alan Man...> ;Magnetic Resonance Imaging. 2008 Jun 1
3 citations
Proton and sodium MRI assessment of fluid level in calf tissue.
Chun S. Zuo, Rosemond A. Villafuerte, Michael E. Henry, Michelle L. Butman, Robert L. Dobbins, Yiwu He, Barbara S. Orban, Kenroy Cayetano, Liqun Wang, Andy Brown, Dere...> ;Journal of Magnetic Resonance Imaging. 2006 Jul 1
3 citations
Increased cardiovascular risk associated with diabetes in Dallas County.
Sandeep R Das, Patrice A. C. Vaeth, Harold G. Stanek, James A. de Lemos, Robert L. Dobbins, Darren K. McGuire> ;American Heart Journal. 2006 May 1
Join now to see all

Other Languages

Italian